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Introduction: In bone metastases, the disruption of normal bone processes results in increased resorption
and formation rates, which can often be quantitatively measured by biomarkers in the urine and blood.
The purpose of this review is to summarize relevant studies of urinary markers used as a diagnostic and/
or prognostic tool, as well as its potential and advances in directing therapy.
Methods: A literature search was conducted using Ovid MEDLINE (1950 to July 2014), EMBASE (1950 to
2014 week 30) and Cochrane Central Register of Controlled Trials (3rd Quarter 2014) to identify studies
that detailed the use of urinary markers in the cancer setting, speciﬁcally involving markers for bone
metastases. Search terms included “urinary markers”, “cancer”, and “bone metastases”.
Results: A total of 35 articles, with 24 original studies, were identiﬁed. In general, urinary markers can be
used to detect early signs of bone metastases prior to skeletal imaging, but still must be used in
conjunction with imaging to avoid false positive results. The use of urinary markers, such as
N-telopeptide, as a prognostic tool remains controversial, but can provide information on the relative
risk of skeletal related events (SREs), disease progression, as well as death. Finally, while urinary markers
have shown to be potentially useful in conﬁrming the efﬁcacy of bone metastases treatments, exploring
the appropriate dosages for treatment, and directing therapy, it is still unclear to what extent urinary
markers should be reduced by.
Conclusion: The potential use of urinary markers in the management of bone metastases is promising as
it can allow for earlier and more convenient detection of bone metastases in comparison to other
techniques. However, additional studies involving prospective clinical trials are suggested to further
examine the potential of urinary markers in developing appropriate treatment strategies and endpoints,
especially in developing a clearer protocol on the extent urinary markers should be reduced by to
correlate with achievement of clinical beneﬁt.
& 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Bone metastases are a common complication in advanced cancer
patients. The incidence of bone metastases at postmortem examina-
tion is 73% for patients with primary breast cancer and 68% for
patients with primary prostate cancer [1]. In bone metastases, what
typically is a tightly regulated process of bone resorption and forma-
tion, is disrupted by the interaction of tumor cells with osteoclasts and
osteoblasts in the bone [2]. The disruption of normal bone processes
by the disease usually results in increased resorption and formation
rates, which can often be quantitatively measured by biomarkers in
the urine and blood of patients.
The focus of this review is on urinary markers. As the process of
urination is a natural body process, obtaining urinary markers is
certainly a very convenient procedure. Examples of urinary mar-
kers include: calcium, hydroxyproline, N-terminal cross-linked
telopeptide of Type I collagen (NTX), and C-terminal cross-linked
telopeptide of Type I collagen (CTX), pyridinoline crosslinks (PYD),
and deoxypyridinoline crosslinks (DPD).
Despite the convenience of urinary markers, their capabilities
should not be underestimated. Urinary markers are still in need of
further validation to enter routine clinical practice; however they
are becoming increasingly important in the management of bone
metastases. Changes in bone are often too slow for detection by
imaging; therefore urinary markers can provide an alternative
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/jbo
Journal of Bone Oncology
http://dx.doi.org/10.1016/j.jbo.2015.01.002
2212-1374/& 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
n Correspondence to: Department of Radiation Oncology, Odette Cancer Centre
Sunnybrook Health Sciences Centre, 2075 Bayview Avenue Toronto, ON Canada
M4N 3M5. #Tel.: þ1 416 480 4998; fax: þ1 416 480 6002.
E-mail address: Edward.Chow@sunnybrook.ca (E. Chow).
Journal of Bone Oncology 4 (2015) 18–23
method to evaluate changes in disease status, even before such
changes become clinically evident. Thus, urinary markers could
potentially serve as a convenient and important diagnostic tool [3].
Many studies over the past 20 years have shown the potential
of urinary markers in the detection of the presence of bone
metastases [3–11], the use of urinary markers for its prognostic
value in bone disease [2,4,12–20], as well as directing therapy for
bone metastases patients [2,6,12–18,21–25]. The purpose of this
review is to summarize relevant studies reporting the potential
and advances in using urinary markers in the management of bone
metastases.
2. Methods
A literature search was conducted using Ovid MEDLINE (1950
to July 2014), EMBASE (1950 to 2014 week 30) and Cochrane
Central Register of Controlled Trials (3rd Quarter 2014) to identify
studies that detailed the use of urinary markers in the cancer
setting, speciﬁcally involving markers for bone metastases. Search
terms included “urinary markers,” “cancer,” and “bone metas-
tases.” Articles written in languages other than English were
omitted from consideration.
3. Results
We identiﬁed a total of 34 articles, with 23 original studies, that
detailed the use of urinary markers as a diagnostic tool, prognostic
tool, or in directing therapy for patients with bone metastases. The
results of the 23 original studies are summarized in Table 1. The
criterion for inclusion was strictly for studies that examined
urinary markers; as such, there are many more studies in the
literature not included that examines other bone markers exclu-
sively. Studies that included both urinary markers and other bone
markers were not omitted.
3.1. Diagnostic use of urinary markers
The diagnostic potential of urinary markers in bone metastases
is documented by seven studies in our search, indicating a
relationship between increasing levels of urinary markers and
the presence of metastatic bone disease [3–11]. Most commonly,
the increase of urinary pyridinoline (PYD) and deoxypyridinoline
(DPD) were seen as a possible indicator for bone metastases
[4–7,10,11].
In a study by Ikeda et al., patients with new or recurrent
prostate cancer with bone metastases were determined to have a
higher urinary excretion of urinary pyridinoline (PYD) and deox-
ypyridinoline (DPD) than patients with benign prostatic hyper-
trophy (BPH), or with prostate cancer and no bone metastases [5].
The authors concluded that PYD and DPD appeared to be a useful
marker for evaluating the activity of bone metastases [5].
Another study by Vinholes et al. conﬁrmed the speciﬁcity of
PYP and DPD as bone resorption markers in patients with bone
metastases [6]. The study found that pyridinoline and deoxypyr-
idinoline levels were increased in 70% of bone metastases patients
when compared to healthy reference controls, while urinary
calcium, previously thought to be a suitable indicator of bone
metastases in early studies [26,27], was increased in only 40% of
patients [6].
Cross-linked C-telopeptide collagen (CTX) and cross-linked
N-telopeptide collagen (NTX) have also been used as urinary
markers with the potential of identifying the presence of bone
metastases [8,9,12,14–16,18]. In the study by Garnero et al., 39
patients with prostate cancer and bone metastases had CTX levels
greater than 149% of healthy control levels [15]. Moreover, there
was no increase in urinary markers for prostate cancer patients
without bone metastases, further highlighting the possibility of
CTX as a bone metastases identiﬁer [15]. Many studies in which
urinary NTX levels were used as a marker for bone metastases
have been reported [14,15,25]. In fact, in a study by Demers et al.,
NTX measurement had the most signiﬁcant association with the
probability of bone metastases of all other urinary markers, with
urinary DPD the second most predictive marker [4]. The signiﬁ-
cance of NTX levels over other markers was also determined in a
study by Lipton et al. [22].
However, while urinary markers show much promise in being
diagnostic tools for patients with bone metastases, urinary mar-
kers are currently not absolutely necessary nor sufﬁcient for the
diagnoses of the disease. Urinary markers can detect early signs of
bone metastases before skeletal imaging, but imaging is still
necessary to diagnose bone metastases with certainty. Elevated
urinary markers may be present even in those without malignant
diseases, which explain why they are always used in conjunction
with imaging to avoid false positive results.
3.2. Prognostic use of urinary markers
The use of urinary markers as a prognostic tool has also been
explored in many studies in the literature [2,4,12–20]. While other
bone markers such as serum bone alkaline phosphatase (BAP) [2],
serum BSP [28], serum PINP [29], and serum ICTP [30] have proved
useful in the prognostic setting, NTX has been shown to be the
most consistent urinary marker for prognostic use [2,30,31].
For example, Brown et al. monitored 238 patients with bone
metastases secondary to prostate cancer, non-small cell lung
cancer (NSCLC), and other solid tumors. Patients with high urinary
NTX levels had an increased relative risk (RR) of SREs, disease
progression, and death compared with patients with low NTX
levels. The authors concluded that baseline NTX levels were most
predictive of negative clinical outcomes [12].
An exploratory cohort analysis by Coleman et al. also found
similar predictive potential in NTX [2]. Urinary measurements of
NTX and serum bone alkaline phosphatase (BAP) were obtained
from 1824 bisphosphonate-treated patients. Patients were
grouped into categories of low (o50 nmol/mmolcreatine), mod-
erate (50–99 nmol/mmolcreatine), or high (4100 nmol/mmol-
creatine) NTX levels. Risk of skeletal complications and disease
progression increased by 2-fold in patients with high and moder-
ate NTX levels compared with patients with low NTX levels.
Compared with patients with low NTX levels, risk of death on
study increased 4- to 6-fold with high NTX levels, and 2- to 4- fold
in patients with moderate levels [2].
Despite many studies supporting the prognostic capability of
urinary markers, there have been a few studies that have not
conﬁrmed these ﬁndings [19,20]. Speciﬁcally, Petriolo et al. found
that bone markers were not prognostic of survival in patients with
hormone-resistant prostate cancer and bone metastases treated
with chemotherapy [19], while Seibel et al. concluded in their
study that bone markers could not predict bone metastases in
breast cancer patients [20]. Siebel later explained that the contra-
diction of conventional results were possibly due to the long-term
variability of markers of bone turnover in patients with breast
cancer [32]. In addition to the risk of attaining false positive results
[33], the variability of markers is another limitation that has
prevented urinary markers from being routinely used in clinical
practice for prognostic value. It also reveals the inconsistency in
results that may arise from similar studies with different patient
cohorts. This heterogeneity should be more clearly distinguished
between studies, and future research should focus on developing
endpoints that are speciﬁc to certain patient cohorts. Nevertheless,
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Table 1
Summary of results from original studies.
Author Study type Population Treatment Markers examined Urinary marker use
Coleman et al.
[2]
Retrospective
review of three
randomized phase
III trials
1824 bone metastases patients
with various primary cancer sites
1462 patients with zoledronic
acid, 362 with pamidronate
Urinary markers: NTX;
Other bone markers: BAP
Prognostic use and directing
therapy; high NTX levels
correlated with increased risk of
skeletal complications, disease
progression and death.
Percherstorfer
et al. [3]
Prospective study 52 lung cancer patients, 27 patients
with bone metastases, 25 without
bone metastases
No treatment Urinary markers: DPD;
Other bone markers:
serum Ca, ALP, BALP, and
osteocalcin
Diagnostic use: all markers were
higher in patients with bone
metastases than those without
bone metastases, with DPD and
BALP being signiﬁcantly higher.
Demers et al.
[4]
Retrospective
review
A total of 94 patients with newly
diagnosed or progressive
malignancy; 30 patients had
metastases to the bone, 50 patients
had metastatic cancer without
overt bone involvement, 13
patients had local disease without
bone metastases
No treatment Urinary markers: PYD,
DPD, and NTX; Other
bone markers: BAP and
ICTP
Diagnostic use; NTX had the most
signiﬁcant association with the
probability of bone metastases.
Ikeda et al. [5] Retrospective
review
15 patients with benign prostatic
hypertrophy (BPH), 17 patients
with carcinoma conﬁned to
prostate, 26 patients with prostate
cancer and bone metastases
No treatment Urinary markers: PYD and
DPD; Other bone
markers: alkaline
phosphatase (ALP)
Diagnostic use; patients with
prostate cancer and bone
metastases had higher PYD and
DPD excretion than did patients
with BPH, or carcinoma conﬁned
to prostate cancer
Vinholes et al.
[6]
Retrospective
review
20 patients with bone metastases
and received at least one infusion
of pamidronate 120 mg
Pamidronate Urinary markers: Calcium,
PYD, and DPD; Other bone
markers: ALP and
hydroxyproline
Diagnostic use and directing
therapy; PYD and DPD appears to
be useful marker in evaluating
activity of bone metastases and
their response to hormonal
treatment in prostate cancer.
Aksoy et al. [7] Retrospective
review
20 patients with BPH, 23 patients
with localized prostate cancer, and
11 patients with prostate cancer
and bone metastases
No treatment Urinary markers: DPD;
Other bone markers: bone
isoenzyme of alkaline
phosphotase (BALP) and
TALP
Diagnostic use: increase in DPD,
BALP, and TALP levels correlated
with the presence of bone
metastases
Piedra et al. [8] Retrospective
review
21 patients with BPH, 31 patients
with prostate carcinoma without
bone metastases, and 15 patients
with bone metastases exclusively
No treatment Urinary markers: NTX,
a-CTX, b-CTX, PINP, and
ICTP; Other bone
markers: BAP
Diagnostic use: these results
support the use of PINP or b-CTX
as a tool to conﬁrm the presence
or the absence of bone metastases
in the ﬁrst staging of prostatic
carcinoma patients.
Dane et al. [10] Retrospective
review
22 patients with lung cancer and
bone metastases, 38 patients with
early stage lung cancer exclusively
No treatment Urinary markers: DPD and
PYD; Other bone markers:
serum osteoalcin, calcium
and total alkaline
phosphotase (T-ALP)
Diagnostic use: high urinary
D-PYD level may be an early sign
of occult metastases in patients
with no bone metastasis assessed
by scintigraphic techniques.
Paterson et al.
[11]
Prospective pilot
study
20 patients with breast cancer, 10
with known bone metastases, 10
with no recognized metastases in
bone
No treatment Urinary markers: PYD and
DPD
Diagnostic use: 8 of 10 patients
with metastases had crosslink
excretion values higher than
reference level indicating that
urinary collagen crosslink assays
may have use in the early
detection of metastatic spread to
bone.
Brown et al.
[13]
Retrospective
review of two
phase III trials of
zoledronic acid;
exploratory cohort
study
441 patients with bone metastases
in total; 203 with prostate cancer,
115 with NSCLC, and 123 with
other solid tumors
Zoledronic acid Urinary markers: NTX;
Other bone markers: BAP
Prognostic use and directing
therapy: baseline and recent bone
marker levels, especially NTX
were predictive of negative
clinical outcomes in patients with
bone metastases secondary to
prostate cancer and to NSCLC and
other solid tumors.
Martinetti
et al. [14]
Prospective cohort
study
42 patients with bone metastases
and various primary cancer sites
Pamidronate Bone markers:
osteocalcin, bone alkaline
phosphotase (BAP), PINP,
ICTP, and NTX, D-PYR OPG
and OPN
Prognostic use and directing
therapy: biochemical markers of
bone turnover, in particular ICTP
and osteoprotegerin seem
promising for predicting and
objectively assessing the analgesic
response to pamidronate
treatment.
Zafeirakis et al.
[15]
Prospective cohort
study
36 patients with prostate cancer
also suffering from bone
metastases, treated with 186Re-
HEDP.
186Re-HEDP Bone markers:
osteocalcin, BAP, PINP,
PICP, NTX, and CTX
Prognostic use and directing
therapy: the best marker-derived
predictors of better and longer
duration of response to 186Re-
HEDP treatment were a post-
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Table 1 (continued )
Author Study type Population Treatment Markers examined Urinary marker use
treatment decrease in NTX of
Z20% and a pretreatment NTX/
PINP ratio of Z1.2.
Garnero et al.
[16]
Prospective cohort
study
39 patients with prostate cancer
and bone metastases, 9 patients
with prostate cancer without bone
metastases, 9 patients with BPH,
and 355 healthy men
Pamidronate Urinary markers: CTX;
Other bone markers:
serum osteocalcin, T-ALP,
BAP, and PICP
Prognostic use and directing
therapy: 39 patients with prostate
cancer and bone metastases had
CTX levels greater than 149% of
healthy control levels. In addition,
pamidronate signiﬁcantly
decreases CTX levels by greater
than 60%.
Berruti et al.
[17]
Prospective study 35 prostate cancer patients with
bone metastases
Pamidronate Urinary markers: Ca, PYD,
DPD, and NTX; Other
bone markers: Ca, TALP,
BGP, and ICTP; Other
markers: Interleukin 6 (IL-
6)
Prognostic use and directing
therapy: pamidronate is able to
induce a decrease in bone
resorption, with NTX being the
most sensitive marker in
bisphosphonate therapy
monitoring; however, changes in
(IL-6), and not bone resorption
markers maybe useful in
prediction of symptomatic
response.
Chow et al.
[18]
Prospective cohort
study
135 patients with bone metastases Palliative radiotherapy Urinary markers: Ca,
creatinine, magnesium,
phosphate, NTX, and PYD
Prognostic use and directing
therapy: baseline levels of urinary
markers could not predict which
patient would beneﬁt from
palliative radiotherapy
Costa et al.
[19]
Prospective study 97 patients with bone metastases
(52 of which also had extraskeletal
metastases) and 26 with
extraosseous disease only
49 patients received
pamidronate, 3 received
clodronate
Urinary markers: NTX;
Other bone markers: BAP
and ICTP
Prognostic use and directing
therapy: with disease progression
in bone, percent change from
mean levels during stable disease
was 152% for NTX and 144% for
ICTP, regardless of the type of
bisphosphonate therapy. NTX also
had the highest positive
predictive value (71%) for the
diagnosis of bone metastases
progression.
Petrioli et al.
[20]
Prospective cohort
study
141 patients with hormone-
resistant prostate cancer and bone
metastases
chemotherapy Urinary markers:
Calcium/creatine ratio;
Other bone markers:
BALP, PICP, and ICTP
Prognostic use: bone markers
were not prognostic of survival in
patients with hormone-resistant
prostate cancer and bone
metastases treated with
chemotherapy
Seibel et al.
[21]
Prospective cohort
study
113 patients with bone metastases
and primary breast cancer
No treatment Urinary markers: PYD,
DPD, NTX, and CTX; Other
serum bone markers: TAP,
BAP OC, PICP, NTX, and
CTX
Prognostic use: 93% of all changes
in bone markers were below the
least signiﬁcant change, as
deﬁned in an independent group
of similar patients. The remaining
7% of values could not be
associated in a consistent pattern
with the occurrence of BM.
Authors conclude that in patients
with primary breast cancer, bone
markers cannot be used to predict
or diagnose incident BM.
Brown et al.
[22]
Prospective
randomized trial
125 patients with bone metastases Clodronate Urinary markers: NTX and
calcium; Other bone
markers: Serum CTX
Directing therapy: the study
found that doses of 41600 mg
clodronate produced mean
reductions of 440% in all three
markers. The study conﬁrmed the
efﬁcacy of the 1600 mg dose as
the most appropriate dose for
patients with primary breast
cancer, but suboptimal for other
(mainly prostate cancer) patients,
who showed more optimal
responses to 2400 mg.
Lipton et al.
[23]
Prospective
randomized
cohort study
52 postmenopausal breast cancer
patients with bone metastases
Pamidronate or placebo with
standard endocrine therapy or
chemotherapy
Urinary markers: PYD,
DPD, and NTX
Directing therapy: Measuring NTX
levels appears useful in
monitoring bisphosphonate
therapy of bone metastases, with
the goal being to normalize NTX
levels.
Vinholes et al.
[24]
52 patients with painful bone
metastases
Urinary markers: Ca and
Hyp; Other collagen
Directing therapy: Symptomatic
response during the ﬁrst four
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urinary markers are useful in that they can help identify patients
who are at high risk of SREs, and allow for early therapeutic
interventions.
3.3. Directing and monitoring therapy
Bisphosphonates have long been used in the treatment of
patients with bone metastases [34]. Its ability to reduce morbidity
and alleviate pain in skeletal metastases is undisputed. However,
there is still a need to develop methods that can determine
therapeutic efﬁcacy and monitor patient response. Urinary mar-
kers have a rapid response to bisphosphonate treatment, and have
proven to be a convenient and useful tool in validating the efﬁcacy
of bone metastases treatments, exploring the appropriate dosage
required for treatment, and potentially helping to direct therapy.
Many studies have explored the use of urinary markers in direct-
ing and monitoring treatment [2,6,12–18,21–25].
A study by Garnero et al. examined the effect of pamidronate
treatment on urinary markers in patients with bone metastases
and prostate cancer. It was found that after bisphosphonate
treatment, the urinary a-CTX, urinary b-CTX and serum CTX,
decreased signiﬁcantly by an average of 65%, 71%, and 61%
respectively within a few days. These ﬁndings, coupled by the
result that no signiﬁcant change was observed for any bone
formation markers, suggest that CTX may be useful for manage-
ment of this group of patients [15]. More importantly, the effect of
bisphosphonates in bone metastases is measured quantitatively.
In addition, urinary markers have also been used to conﬁrm the
efﬁcacy of appropriate dosages for treatment. For example, Brown
et al. explored the dose-response relationship of clodronate with
markers urinary NTX, serum CTX, urinary calcium, and BAP,
measured weekly for a 6-week treatment period. 125 patients
with bone metastases were randomized to daily oral clodronate
(800, 1600, 2400, and 3200 mg). The study found that doses of
41600 mg clodronate produced mean reductions of 440% in all
three markers. The study conﬁrmed the efﬁcacy of the 1600 mg
dose as the most appropriate dose for patients with primary breast
cancer, but suboptimal for other (mainly prostate cancer) patients,
who showed more optimal responses to 2400 mg [21].
Finally, a study by Zafeirakis et al. highlighted the use of urinary
markers in directing treatment. In this prospective study, bone
markers such as PINP, PICP, NTX and CTX were compared with the
level and duration of pain response to radionuclide treatment in
36 men with prostate cancer suffering from osseous metastases.
According to multivariate and ROC analyses, the best marker-
derived predictors of better and longer duration of response to
186Re-HEDP treatment were a post-treatment decrease in NTX of
Z20% and a pretreatment NTX/PINP ratio of Z1.2. This study
shows the usefulness of urinary markers in providing cut-off
values for a cohort of patients that do not respond to a certain
palliative treatment, thereby helping patients to avoid inefﬁcient
and expensive treatment [14].
Despite promising results showing the use of urinary markers in
directing therapy, the exact amount that urinary markers should be
reduced by as indication of treatment success remains unknown [35].
Although some studies have shown that only patients with normal-
ized urinary markers following bisphosphonate treatment experience
a signiﬁcant improvement in pain and related symptoms [23,24],
whether to normalize NTX, reduce NTX by an absolute or a propor-
tional amount, or merely stabilize baseline levels as a way of aiming at
optimally improved patient outcomes is still unclear and requires
additional long term studies [35].
4. Conclusion
The use of urinary markers in diagnosing, prognosticating, and
directing therapy for bone metastases patients is well documented
in the literature. In general, the urinary markers can detect early
signs of bone metastases before skeletal imaging, but are still only
used in conjunction with more established imaging techniques to
avoid false positive results. The use of urinary markers as a
prognostic tool, though not completely conclusive, especially in
primary breast cancer patient cohorts, can provide information on
the RR of SREs, disease progression, as well as death. Finally, while
urinary markers have shown to be potentially useful in directing
therapy, it is still unclear to what extent urinary markers should be
reduced by. Further studies involving prospective clinical trials are
suggested to further examine the potential of urinary markers in
developing appropriate treatment strategies and endpoints, espe-
cially in developing a clearer protocol on the extent urinary
markers should be reduced by to correlate with achievement of
clinical beneﬁt. Until then, urinary markers should not be used in
isolation in routine clinical settings.
Table 1 (continued )
Author Study type Population Treatment Markers examined Urinary marker use
Prospective
randomized
double-blind trial
Two-hour infusion of
pamidronate 120 mg or
identical infusion of saline
breakdown products: NTX
and DPD
weeks was seen after
pamidronate, but not with
placebo. Beneﬁt of intravenous
pamidronate is conﬁrmed, with
NTX levels decreasing by 70%
after treatment.
Jagdev et al.
[25]
Prospective
randomized trial
51 patients with bone metastases Oral clodronate 1600 mg
daily, intravenous clodronate
followed by same schedule of
oral clodronate, intravenous
pamidronate 90 mg monthly
Urinary markers: CTX and
NTX
Directing therapy: intravenous
pamidronate appears to be more
effective than oral clodronate in
both controlling symptoms and
suppressing bone resorption.
Hoskin et al.
[26]
Prospective cohort
study
22 patients with bone metastases
and various primary cancer sites
Radiotherapy Urinary pyridinium and
PICP
Directing therapy: an association
was shown between relief of
metastatic skeletal pain by
radiotherapy and low marker
concentrations before and after
treatment, lending support to the
hypothesis that relief of
metastatic bone pain by
radiotherapy relates to an effect
on bone, rather than tumour
physiology.
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